Actively Recruiting
StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias
Led by University Health Network, Toronto · Updated on 2026-03-05
60
Participants Needed
1
Research Sites
311 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-center, phase II trial that will be monitoring the safety and efficacy of using stereotactic ablative radiotherapy (SBRT) to treat patients with a medical condition affecting heart rate and rhythm (refractory arrhythmias) within the University Health Network (Princess Margaret Cancer Centre and Toronto General Hospital). The primary objective will be to prospectively monitor patient cardiac outcomes following SBRT.
CONDITIONS
Official Title
StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with heart rate and rhythm condition (arrhythmia) who have failed standard of care treatment with medication OR at least one prior invasive catheter ablation procedure.
- Patients deemed medically fit to receive stereotactic ablative radiotherapy as determined by their Radiation Oncologist.
You will not qualify if you...
- Patients who have previously received high dose radiotherapy to the target area and cannot safely receive further treatment OR are unable to receive radiotherapy due to other contraindications.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Center, University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
B
Benjamin Lok, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here